Verona Pharma PLC ADR I9SA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $14.30
- Day Range
- $13.90–13.90
- 52-Week Range
- $3.32–24.00
- Bid/Ask
- $14.40 / $14.60
- Market Cap
- $1.13 Bil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 79
- Website
- https://www.veronapharma.com
Valuation
|
Metric
|
I9SA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.55 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
I9SA
|
|---|---|
Quick Ratio | 18.03 |
Current Ratio | 18.40 |
Interest Coverage | −21.63 |
Quick Ratio
I9SA
Profitability
|
Metric
|
I9SA
|
|---|---|
Return on Assets (Normalized) | −16.02% |
Return on Equity (Normalized) | −18.88% |
Return on Invested Capital (Normalized) | −19.57% |
Return on Assets
I9SA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Bgfmpsp | Zzwjjrc | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Cnwcnfbpr | Hdbcg | $114.2 Bil | |||
| Moderna Inc
MRNA
| Dkvqfrsk | Hhmd | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Mykgclnl | Vnkhb | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Yzlvpmb | Jqb | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vkgrjsmdm | Mhflb | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Vlljgstp | Rcgkd | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Nnnzmkbr | Wdg | $12.8 Bil | |||
| Incyte Corp
INCY
| Qkvqhhg | Rrkjt | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Sfwplknbhy | Svxqj | $12.2 Bil |